Clarithromycin and simvastatin — GPhC CRA MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: E — Increased simvastatin exposure with myopathy risk
Clarithromycin inhibits metabolism of simvastatin and increases muscle toxicity risk. The best answer addresses the key safety, legal or pharmaceutical care issue in the vignette. The other options would either delay appropriate care, create a new risk, or fail to resolve the issue. This is consistent with the cited UK reference for safe pharmacy practice.
Reference: BNF; NICE CKS; NICE antimicrobial prescribing guidance